Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Relief Therapeutics Hldg
(OP:
RLFTF
)
0.5534
+0.0434 (+8.51%)
Streaming Delayed Price
Updated: 9:48 AM EDT, Mar 23, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Relief Therapeutics Hldg
< Previous
1
2
3
4
5
6
7
Next >
Relief Therapeutics Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphom
January 17, 2023
Via
ACCESSWIRE
Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission
December 27, 2022
Via
ACCESSWIRE
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements
December 20, 2022
Via
ACCESSWIRE
Relief Therapeutics Announces Executive Leadership Team Changes
December 08, 2022
Via
ACCESSWIRE
Relief Therapeutics Announces Six-Month Stability Data on a New Formulation of RLF-100 (Aviptadil)
November 07, 2022
Via
ACCESSWIRE
Relief Therapeutics to Participate in January Investor Meetings
December 14, 2022
Via
ACCESSWIRE
Relief Therapeutics Announces Issuance of Shares from Authorized Capital
December 13, 2022
Via
ACCESSWIRE
APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the 2022 Rare Disease International Film Festival
November 21, 2022
Via
ACCESSWIRE
Relief Therapeutics Files Amendment No. 1 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission
November 16, 2022
Via
ACCESSWIRE
Relief Announces U.S. Launch of PKU GOLIKE
October 10, 2022
Via
ACCESSWIRE
Relief Announces Exclusive Distributor for PKU GOLIKE in the U.S.
October 06, 2022
Via
ACCESSWIRE
Relief Therapeutics Appoints David McCullough as Head of U.S. Market Access
August 17, 2022
Via
ACCESSWIRE
Relief Therapeutics, NRx Pharma Settle Litigation Regarding COVID-19 Treatment Candidate
↗
November 14, 2022
Via
Benzinga
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Definitive Settlement Agreements
November 14, 2022
Via
ACCESSWIRE
Relief Therapeutics Holding SA and NRx Pharmaceuticals, inc. Further Extend their Stay of Pending Litigation to Provide Additional Time for the Parties to Finalize their Litigation Settlement
November 08, 2022
Via
ACCESSWIRE
RELIEF THERAPEUTICS Holding SA and NRx Pharmaceuticals, Inc. Extend Their Stay of Pending Litigation to Provide Additional Time for The Parties to Finalize Their Settlement
October 26, 2022
Via
ACCESSWIRE
Relief Therapeutics Files Amendment No. 2 to its Form F-6 Registration Statement with the U.S. Securities and Exchange Commission
October 25, 2022
Via
ACCESSWIRE
Relief Therapeutics Announces Promotion of Paolo Galfetti to Chief Operating Officer
October 14, 2022
Via
ACCESSWIRE
Relief Therapeutics Announces IRB Approval and Initiation of an Investigator Initiated Trial of Nexodyn for Epidermolysis Bullosa at Ann & Robert H. Lurie Children's Hospital of Chicago
September 22, 2022
Via
ACCESSWIRE
Relief Reports Half-Year 2022 Results and Provides Corporate Update
September 15, 2022
Via
ACCESSWIRE
Relief Therapeutics to Participate in the 22nd Annual Biotech in Europe Forum
September 12, 2022
Via
ACCESSWIRE
Relief Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
September 07, 2022
Via
ACCESSWIRE
Relief Therapeutics Files Registration Statement on form F-1 with the U.S. Securities and Exchange Commission
August 24, 2022
Via
ACCESSWIRE
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Tentative Settlement of Pending Litigation
August 22, 2022
Via
ACCESSWIRE
Relief Therapeutics Announces Promising Initial Stability Data on a New Formulation of RLF-100(R) (Aviptadil)
August 03, 2022
Via
ACCESSWIRE
Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate
↗
July 28, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Relief Therapeutics Announces Effectiveness of Registration Statement on Form 20-F
July 21, 2022
Via
ACCESSWIRE
Relief Therapeutics Announces Effectiveness of Registration Statement on Form 20-F
July 21, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / July 21, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief ") announced today that the U.S. Securities and Exchange Commission (" SEC ")...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Regulatory Compliance
Relief Therapeutics Announces that its Collaboration Partner has Resubmitted the ACER-001 (Sodium Phenylbutyrate) New Drug Application (NDA) to the FDA for the Treatment of Urea Cycle Disorders (UCDs)
July 18, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / July 18, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief), today announced that its collaboration partner, ACER Therapeutics, Inc....
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Therapeutics Appoints Serene Forte, Ph.D., MPH, as Senior Vice President, Head of Genetic Medicine
July 18, 2022
Experienced Leader in Commercial and Medical Affairs, With a Focus on Gene Therapy, to Spearhead Relief's New Strategic Foray Into Genetic Medicine
From
Relief Therapeutics Holdings AG
Via
AccessWire
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
